ROAR Awards shortlist announced

The Rare & Orphan Advocacy &Research (ROAR) Awards have been hotly contested for a second year, and following over 1500 nominations the shortlist has now been compiled. (You can see last year’s winners here.)

This list is taken directly from peer nominations and so are a great reflection of the rare disease sector successes in the past year. The winners will be chosen by a peer-nominated judging panel and announced on day two of the World Orphan Drug Congress, running from 12-14 November.

The shortlist revealed:

Outstanding CRO

Orphan Reach

PRA

Premier Research

PSR-Agility

Quintiles

Outstanding Market Access

Evidera

Clinigen

Covance

Mapi

Navigant Consulting

Outstanding Innovation

Pfizer Inc. and the Global Medical Excellence Cluster (GMEC) for their collaboration aimed at accelerating the translation of basic science into a new generation of innovative medicines for rare diseases.

SOBI for their part in the Work on Mechanism of Coordinated Access for Orphan Medicinal Products

AstraZeneca and their driving force in Lipodystrophy CONNECT. Dr. Isupov was highlighted in terms of ensuring the data is accessible – even to competitive pharmaceutical companies.

PTC Therapeutics for their conditional marketing permission from European Commission for Translarna (ataluren) as this is the first DMD treatment approved in EU.

Join us for the ROAR Awards in Brussels to see who wins and then network with the whole shortlist and your peers at the Back To The Future After Party. Book your place today for the World Orphan Drug Congress.